Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gene Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT03645200
What this trial is testing

Treatment of Carrying TP53 Harmful Mutations

Who this might be right for
Advanced Cancer
Tianjin Medical University Second Hospital 60
Early research (Phase 1)Study completedNCT01225536
What this trial is testing

Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

Who this might be right for
Solid Tumor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 24
Testing effectiveness (Phase 2)Study completedNCT00588445
What this trial is testing

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Who this might be right for
Lung CancerNon-small Cell Lung CancerBronchioloalveolar Cancer
Memorial Sloan Kettering Cancer Center 65
Testing effectiveness (Phase 2)Looking for participantsNCT04090567
What this trial is testing

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)Looking for participantsNCT07505173
What this trial is testing

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Who this might be right for
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital 74
Not applicableTemporarily pausedNCT06465537
What this trial is testing

CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation

Who this might be right for
Primary Open Angle Glaucoma
Shanghai BDgene Co., Ltd. 9
Not applicableStudy completedNCT04236102
What this trial is testing

KEBI-Cyto Study - Use of the Biocartis Idylla

Who this might be right for
Pancreatic AdenocarcinomaLung Cancer
Royal Cornwall Hospitals Trust 55
Not applicableUnknownNCT05087953
What this trial is testing

Autonomic Evaluation of Patients With Hereditary Amyloidotic Cardiomyopathy: Hereditary Amyloidotic Heart Disease

Who this might be right for
Autonomic Nervous System DiseaseAmyloid Neuropathies
University of Sao Paulo General Hospital 60
Testing effectiveness (Phase 2)Study completedNCT00375219
What this trial is testing

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Who this might be right for
Chronic Myeloid Leukemia
Teva Branded Pharmaceutical Products R&D, Inc. 103
Not applicableEnded earlyNCT01103128
What this trial is testing

Validation of a Mouse Model of Pancreatic Carcinogenesis

Who this might be right for
Pancreatic Cancer
Columbia University 450
Testing effectiveness (Phase 2)Study completedNCT01898312
What this trial is testing

BRCA1/2 and Effect of Mifepristone on the Breast

Who this might be right for
Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2
Karolinska Institutet 45
Not applicableStudy completedNCT03802812
What this trial is testing

Thin Bronchoscope and Virtual Bronchoscopic Navigation System for Tuberculosis

Who this might be right for
Tuberculosis
Pusan National University Hospital 88
Not applicableStudy completedNCT01783795
What this trial is testing

Dent Disease Mutation Genotyping

Who this might be right for
Dent Disease
Mayo Clinic 180
Early research (Phase 1)Looking for participantsNCT06186401
What this trial is testing

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Who this might be right for
EGFR Gene MutationGlioblastomaMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD 20
Not applicableUnknownNCT05411276
What this trial is testing

A Real-World Study of Pyrotinib Maleate in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer With Rare Mutations in HER2

Who this might be right for
HER2 Mutant Non-small Cell Lung Cancer
Beijing Chest Hospital 15
Testing effectiveness (Phase 2)UnknownNCT06492850
What this trial is testing

Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa

Who this might be right for
X-Linked Retinitis Pigmentosa (XLRP)
Frontera Therapeutics 32
Not applicableLooking for participantsNCT07432880
What this trial is testing

A Prospective Study of Pediatric Participants up to 16 Years of Age With Methylmalonic Acidemia (MMA) Due to Mutations in the MMUT Gene

Who this might be right for
Methylmalonic Acidemia (MMA)
Genespire Srl 30
Not applicableStudy completedNCT02047903
What this trial is testing

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 161
Large-scale testing (Phase 3)Study completedNCT03293524
What this trial is testing

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

Who this might be right for
Leber Hereditary Optic Neuropathy
GenSight Biologics 98
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06275620
What this trial is testing

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

Who this might be right for
X-Linked Retinitis Pigmentosa
Beacon Therapeutics 24
Next Page